“…However, even given some inherent vulnerability, long-term neuroleptic treatment has more profound effects. Novel antipsychotic agents reduce risks of long-term neurological problems, but several (e.g., clozapine, olanzapine and to a lesser extent quietapine) contribute to rates of obesity and diabetes that exceed those associated with conventional agents (Melkersson & Dahl, 2004;Sernyak, Leslie, Alarcon, Losonczy, & Rosenheck, 2002;Wirshing, Pierre, Erhart, & Boyd, 2003).…”